Based on the available information, there is no definitive answer regarding how a patient's weight directly affects the effectiveness of Cosentyx. However, there are some insights that can be gathered from the provided sources.

Cosentyx, also known as secukinumab, is a biologic medication used to treat various conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1][2]. Its effectiveness is generally evaluated based on clinical trials and real-world evidence.

One of the sources, a study published in the National Center for Biotechnology Information, discusses the effectiveness of Cosentyx in patients with obesity and psoriasis [3]. The study suggests that obesity may affect the response to Cosentyx, but it does not provide a clear conclusion on how weight directly influences the drug's effectiveness.

Novartis, the manufacturer of Cosentyx, does not mention weight as a factor affecting the drug's effectiveness in their prescribing information [2]. However, they do acknowledge that higher body weight may affect the dosing of Cosentyx in some cases.

In summary, while there is some evidence suggesting that a patient's weight may influence the effectiveness of Cosentyx, there is no clear or definitive answer on how weight directly affects the drug's efficacy. Further research is needed to better understand the relationship between a patient's weight and Cosentyx's effectiveness.

Sources:

[1] DrugPatentWatch. (n.d.). Biologics: Tradename: COSENTYX. Retrieved from <https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX>

[2] Novartis. (2021). Cosentyx (secukinumab) Prescribing Information. Retrieved from <https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf>

[3] Armstrong, A. W., & Rivas, M. (2021). Secukinumab for Psoriasis in Obese Patients. American Journal of Clinical Dermatology, 22(3), 417–421. <https://doi.org/10.1007/s40257-021-00616-3>